KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to -$7.7 million.

  • Arbutus Biopharma's Net Income towards Common Stockholders rose 60.81% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 44.89%. This contributed to the annual value of -$69.9 million for FY2024, which is 4.02% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Net Income towards Common Stockholders of -$7.7 million as of Q3 2025, which was down 408.95% from $2.5 million recorded in Q2 2025.
  • Arbutus Biopharma's Net Income towards Common Stockholders' 5-year high stood at $2.5 million during Q2 2025, with a 5-year trough of -$24.5 million in Q1 2025.
  • For the 3-year period, Arbutus Biopharma's Net Income towards Common Stockholders averaged around -$15.7 million, with its median value being -$17.9 million (2024).
  • The largest annual percentage gain for Arbutus Biopharma's Net Income towards Common Stockholders in the last 5 years was 112.64% (2025), contrasted with its biggest fall of 37.33% (2025).
  • Arbutus Biopharma's Net Income towards Common Stockholders (Quarterly) stood at -$21.9 million in 2021, then decreased by 0.17% to -$21.9 million in 2022, then grew by 11.95% to -$19.3 million in 2023, then soared by 35.28% to -$12.5 million in 2024, then skyrocketed by 60.81% to -$7.7 million in 2025.
  • Its Net Income towards Common Stockholders was -$7.7 million in Q3 2025, compared to $2.5 million in Q2 2025 and -$24.5 million in Q1 2025.